NICOLAS MAETERLINCK/BELGA MAG/AFP via Getty Images
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own.
The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s Covid shot going forward as well as to try to combine the vaccine with Sanofi’s own flu shot. The pact includes a $500 million upfront payment, with up to $700 million more on the table if certain regulatory and launch milestones are reached.
advertisement
While Novavax’s stock soared during the pandemic as the vaccine race was underway, the company failed to get its shot authorized in the U.S. market until July 2022, long after the makers of mRNA vaccines had reaped billions in sales. Sales have sputtered along since then, and last year, the Maryland-based company warned that that it may not be able to stay in business.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
$39/month Get Started
Totals $468 per year
Starter
$30
for 3 months, then $39/month
$30 for 3 months Get Started
Then $39/month
Annual
$399
Save 15%
$399/year Get Started
Save 15%
11+ Users
Custom
Savings start at 25%!
Request A Quote Request A Quote
Savings start at 25%!
2-10 Users
$300
Annually per user
$300/year Get Started
$300 Annually per user
View All Plans
Get unlimited access to award-winning journalism and exclusive events.
